Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (258) Crinone 8% (progesterone gel), Wyeth,
...Newly Approved Drug Therapies (258) Crinone 8% (progesterone gel), Wyeth, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Crinone 8% (progesterone gel) Company: Wyeth Approval Status: Approved May 1997 Treatment Area: progesterone deficiency General Information Crinone ...
View Page

2.  Study Posting (4846) Trial #117109, Breast Cancer, Madrid, Spain
...Cancer, Madrid, Spain Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

3.  Study Posting (4846) Trial #117108, Breast Cancer, Lleida, Spain
...Cancer, Lleida, Spain Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

4.  Study Posting (4846) Trial #117107, Breast Cancer, Barcelona, Spain
...Cancer, Barcelona, Spain Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

5.  Study Posting (4846) Trial #117106, Breast Cancer, Modena, Italy
...Cancer, Modena, Italy Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

6.  Study Posting (4846) Trial #117104, Breast Cancer, Paris, France
...Cancer, Paris, France Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

7.  Study Posting (4846) Trial #117101, Breast Cancer, Bruxelles, Belgium
...Cancer, Bruxelles, Belgium Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

8.  Study Posting (4846) Trial #117100, Breast Cancer, Bruxelles, Belgium
...Cancer, Bruxelles, Belgium Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

9.  Study Posting (4846) Trial #117112, Breast Cancer, Houston, TX
...Cancer, Houston, TX Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

10.  Study Posting (4846) Trial #117119, Breast Cancer, Pittsburgh, PA
...Cancer, Pittsburgh, PA Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

11.  Study Posting (4846) Trial #117114, Breast Cancer, Philadelphia, PA
...Cancer, Philadelphia, PA Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

12.  Study Posting (4846) Trial #117115, Breast Cancer, Bronx, NY
...Cancer, Bronx, NY Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

13.  Study Posting (4846) Trial #117113, Breast Cancer, Boston, MA
...Cancer, Boston, MA Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

14.  Study Posting (4846) Trial #117121, Breast Cancer, Maywood, IL
...Cancer, Maywood, IL Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

15.  Study Posting (4846) Trial #117111, Breast Cancer, Jacksonville, FL
...Cancer, Jacksonville, FL Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

16.  Study Posting (4846) Trial #117117, Breast Cancer, Aurora, CO
...Cancer, Aurora, CO Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

17.  Study Posting (4846) Trial #117103, Breast Cancer, Toulouse Cedex 3, France
...Cedex 3, France Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

18.  Study Posting (4846) Trial #117105, Breast Cancer, Saint Herblain, France
...Saint Herblain, France Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

19.  Study Posting (4846) Trial #117102, Breast Cancer, Dijon Cedex, France
...Dijon Cedex, France Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page

20.  Study Posting (4846) Trial #117110, Breast Cancer, Chapel Hill, NC
...Chapel Hill, NC Trial Information Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer This study will ...
...CenterWatch Clinical Research Trial Posting: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer ...
View Page